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Abstract: 
EGF signaling activates multiple pathways within the cell that lead towards 
proliferation, rendering this pathway of interest for cancer therapy.  Recent studies 
focused on triple-negative breast cancer have shown that EGF-induced tumorigenesis 
strongly correlates with the up-regulation of FABP5, which shuttles fatty acids from the 
cytoplasm of cells to the nucleus.  Our work began with the identification of redox active 
cysteine residues upon EGF activation in situ using a caged electrophile to perform live 
cell labeling.  In these studies, the C120 residue of FABP5 was identified as a cysteine 
with high redox activity and thus became a subject of further interest.  The 
characterization of redox active cysteine residues yields important information about 
protein structure and function.  We have confirmed these results via in-gel fluorescence 
and developed fluorescence assays to probe the significance of C120 and C127 in 
FABP5.  Two fatty acids were chosen based on their conformation in the FABP5 binding 
pocket.  Upon the addition of a fatty acid, wild type protein showed a decrease in 
fluorescence indicating that the fatty acids were outcompeting the fluorophores used.  
Future studies will investigate both wild type and mutant versions of FABP5 with 
emphasis on determining potential disulfide bond formation via phosphoproteomics and 
western blotting techniques.  
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Chapter 1: Introduction 
1.1 Epidermal Growth Factor Signaling 
1.1.1 Pathway and Cancer Relevance 
Cell growth and proliferation processes are a normal part of the cell life cycle, 
which ends with cell death or apoptosis.  EGF signaling is a common cell-signaling 
cascade that promotes cell growth and inhibits apoptosis.  Elucidating the steps in 
this signaling pathway is a laborious process due to the sheer number of signaling 
components that are activated before nuclear receptors are even reached.  For 
simplicity, the PI3K/AKT pathway is shown below to illustrate the ability of EGF 
signaling to inhibit apoptosis and promote cell growth.   
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Figure 1.1  EGF signaling via the PI3K/AKT pathway.  Autophosphorylation of 
EGFR upon EGF biding and dimerization activates the PI3K/AKT signaling 
pathway.  Activated AKT can then inhibit BAX and/or FOXO which down-regulate 
apoptosis, or activate the mTOR pathway leading to cell growth. 
 
EGF is a small 6kDa protein naturally produced by cells in the body and is part of a 
family of EGF proteins that also includes TGF-α.1  These growth factors have 
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minimal secondary structure save for three disulfide bonds.2  Both EGF and TGF-α 
bind cell surface tyrosine kinase receptors EGFR, ERBB2 (HER2), ERBB3 (HER3), 
and ERBB4 (HER4), which can then form either homo- or heterodimers.1  All of 
these receptors are embedded in the cell membrane with an EGF-binding domain of 
two globular handles outside the cell and a tyrosine kinase enzymatic domain in the 
cytosol.3  The extracellular domain responsible for dimerization and the membrane 
embedded portion of the receptor is rigidified with many cysteine residues.3  When 
EGF binds, one of the cysteine-rich rods of the extracellular region is released to 
allow dimerization with another receptor.3   This also brings the two receptor 
tyrosine kinase domains in close proximity so they are able to phosphorylate one 
another.3  Once dimerized, and autophosphorylation occurs,  the receptor tyrosine 
kinase domain recruits PI3K.1  PI3K is a dimeric enzyme composed of a regulatory 
subunit, p85, and a catalytic subunit, p110.4  The regulatory subunit binds with the 
highest affinity for HER3 surface receptor and the catalytic subunit phosphorylates 
membrane-bound PIP2 to form PIP3.4  PIP3 then recruits AKT to the cell membrane 
because the 120 amino acid region of AKT known as the pleckstrin homology 
domain has high binding affinity to PIP3.5  At the same time, PDK1 interacts with 
another PIP3 and AKT to phosphorylate AKT T308.6  To become fully 
functionalized, AKT is then phosphorylated at the S473 by mTORC2 away from the 
cell membrane.5 To halt phosphorylation of AKT, a tumor suppressor, PTEN 
dephosphorylates PIP3 and when not properly functioning, leads to cancer in the 
form of gioblastomas in humans.7  To continue the pathway, fully activated AKT has 
a variety of substrates that lead to up-regulation of cell growth and proliferation and 
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down-regulation of tumor suppression and apoptosis.  Briefly, one pathway that 
activates cell proliferation is the mTOR pathway where AKT inhibits TSC1-2 which 
releases RHEB from mTORC1.8  Activated mTORC1 can then signal S6K in the 
nucleus to promote cell growth by binding to the large subunit of ribosomes, causing 
them to translate mRNA into protein.8  Activated AKT can also prevent cell death by 
either binding BAX which normally creates holes in the mitochondrial membranes 
leading to apoptosis, or binding FOXO and phosphorylating it.9,10  Phosphorylated 
FOXO is a substrate for ubiquitin ligase, which degrades the tumor suppressor via a 
protease.10  This brief summary of the PI3K/AKT pathway activated by EGF 
stimulation does not encompass all signaling mechanisms that occur.   
Now that the basic EGF signaling pathway has been elaborated on, its 
physiological and pathological effects can be discussed.  Physiologically, EGF 
signaling promotes cell proliferation and survival.  Therefore the main purposes of 
this pathway are closely linked to an organism’s development into adulthood and 
cell turnover including wound healing.  Studies on both the over stimulation with 
EGF and over expression of EGFR coupled with EGFR knockouts have proven that 
a balance of signaling is essential for proper development in embryonic mice.11  
Knockout mice in particular showed severe growth inhibition and multiple organ 
failure before reaching maturity with the worst-case scenario as mid-gestational 
death.11  If they survive birth, the mice show severe abnormalities in skin, lungs, the 
gastrointestinal tract, brain, and liver highlighting the breadth of influence EGFR 
carries.11  However if TGFα-null mice are observed, the phenotype is wavy fur and 
whiskers implying it’s importance as a signaling molecule in the epidermis but also 
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showing that other signaling peptides are able to compensate and prevent severe 
deformity.12  Since EGFR is one of four homologues that can form homo- and 
heterodimers in the ErbB family, each combination with a preference for different 
signaling peptides like EGF, it comes as little surprise that when knocking out 
receptors or ligands, there is some compensation in signaling.  Overexpression of 
EGFR caused mice to spontaneously grow tumors.12  One particular mouse model 
expressed a common mutation to the EGFR called EGFRvIII where exons 2-7 are 
deleted yielding a protein that lacks the majority of the extracellular domain.13-14  
The cell interprets this as a constantly activated receptor and thus this mutation is 
seen in 40-50% of grade VI glioblastomas and in up to 70% of medulloblastomas 
with a small proportion of breast and ovarian carcinomas.15-16  Interestingly the 
overexpression of signaling ligand TGFα does show increased cell proliferation but 
mainly in the form of psoriasis and development of papillomas at the site of a wound 
without progression to carcinomas.17-18  Clearly the relationship between EGF ligand 
and EGFR binding can have a varied effect on cell proliferation and cancer 
pathology, making it a hot target for the development of anti-cancer drugs and 
therapies. 
With so many components to the EGF signaling pathway, each becomes a 
potentially druggable target. The first druggable target is EGFR, which has two 
major drug types on the market currently: tyrosine kinase small molecule inhibitors 
and monoclonal antibody therapies.  Popular tyrosine kinase inhibitors include 
gefitinib (Iressa) and erlotinib (Tarceva), which target the ATP binding site, K745, 
in the tyrosine kinase region of EGFR.19. Resistance to these drugs is the 
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responsibility of mutations near this binding site including T790M and L858R, 
which has mainly been studied in NSCLC, the leading cause of cancer death in the 
United States.19-20  Monoclonal antibody therapies include cetuximab (Erbitux) and 
panitumumab (Vectibix), which targets the ligand binding domains of untethered 
EGFR so that it cannot be activated.21  These therapies are mostly limited by 
differences between ErbB family members.21  The next potential target for anti-
cancer therapies is PI3K.  Idelalisib is a small molecule ATP binding inhibitor that 
targets the p110δ (one of four isoforms of p110) subunit of PI3K.22  Other small 
molecule inhibitors that specifically target the PI3K ATP binding pocket include 
Wortmannin, LY294002, Quercetin, Myricetin, and Staurosporin which all have 
multi-ring structures.23  Of these, all are reversible inhibitors except for Wortmannin, 
which forms a covalent bond with K833.23  Another potential target in the EGF 
signaling pathway is tumor suppressor PTEN.  Restoring activity to PTEN or other 
tumor suppressors in systems where they have lost function has proven more 
difficult than targeting oncogenes and components that have a gain of function.24  
Therefore as an example of a therapy involving PTEN, an ErbB2-targeting antibody, 
trastuzumab (Herceptin) has been explored.25  Nagata et. al. were able to 
demonstrate that treatment with trastuzumab caused PTEN to localize at the cell 
membrane and activate it’s phosphatase activity by reducing PTEN tyrosine 
phosphorylation.25  For patients with PTEN-deficient breast cancers it was shown to 
resist treatment with trastuzumab.25  The next major component of the EGF 
signaling pathway, AKT, has a much larger pool of therapies for treatment of excess 
cell growth and proliferation.  On in particular, an allosteric inhibitor, MK-2206, has 
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been shown to enhance the efficacy of cancer treatment cocktails including treatment 
with erlotinib or LY294002.26  Another inhibitor, Afuresertib, is a reversible ATP 
competitive inhibitor for AKT.27  It is currently in phase IIa clinical trials and has 
shown tolerable side effects for patients suffering a rare disease, Langerhans cell 
histiocytosis.27  Other inhibitors of AKT include GSK690693, AKT inhibitor VIII, 
and AKT inhibitor IV, which do not have any structural relevance but all cause a 
decrease in cell viability and apoptosis by out-competing ATP.28  The last major 
marker of the EGF signaling pathway is mTOR.  When discussing therapies for 
targeting mTOR, they most likely refer to the targeting of mTOR1 specifically since 
mTOR2 is not specific to rapamycin and selective inhibition has been elusive.29  
Two molecules, pyrazolopyrimidines, that specifically target mTOR are PP242 and 
PP30 and work as ATP-competitive inhibitors to prevent phosphorylation of S473 
on AKT.29  Although rapamycin, also termed Rapamune or sirolimus, has been used 
for a longer period of time to target mTOR and reduce cell proliferation, these 
inhibitors show stronger efficacy in preliminary studies.29  Other drugs, temsirolimus 
(Torisel) and everolimus (Afinitor), are used to target mTOR by forming a complex 
with an abundant intercellular protein, FKBP-12, that then complexes with mTOR to 
deactivate it.30-31  From all of the various drugs listed, the EGF signaling pathway 
has clearly been a considerable target of interest for cancer therapies.  Limitations 
usually appear in the form of binding specificity and ability to permeate the cell 
membrane without causing intolerable side effects.  However, factors besides protein 
phosphorylation play major roles in cell signaling and cancer cell growth including 
ROS.  
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1.1.2 Production of Reactive Oxygen Species 
EGF signaling is known to produce ROS in the form of hydrogen peroxide and 
basal levels of ROS in the low-nanomolar to low-micromolar range act as signaling 
molecules.32-34  However, if overproduced, ROS can have destructive oxidative 
effects on many cellular components leading to cell proliferation associated with 
cancer.32  ROS is a broad term used to encompass a variety of oxidative species 
including singlet oxygen (1O2), superoxide anion radical (O2-), hydrogen peroxide 
(H2O2), and hydroxyl radical (OH).32  As described previously, EGF binds EGFR 
and through phosphorylation signaling, activates PI3K.1  PI3K then phosphorylates 
PIP2 to PIP3, which then activates the AKT signaling pathway. 
 
Figure 1.2  Production of hydrogen peroxide as it relates to EGF signaling.  
Activation of the PI3K/AKT pathway not only down-regulates apoptosis and up-
regulates cell growth but can also produce hydrogen peroxide ROS when PIP3 
activates NOX.  Hydrogen peroxide can inhibit PTEN by oxidizing cysteine residues 
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to form a disulfide bond, allowing PIP3 to remain activated and promoting activation 
of the PI3K/AKT pathway. 
 
PIP3 also activates NADPH oxidase, NOX1, complex, as shown above, which 
enzymatically removes electrons from NADPH and reduces oxygen at the cellular 
membrane to give superoxide anions.35  This generation of ROS is extracellular and 
although many believe hydrogen peroxide simply diffuses across the membrane, 
mounting evidence shows that a nearby aquaporin channel translocation is 
preferred.36-38  Once in the cell, these ROS can be reduced to molecular oxygen and 
hydrogen peroxide via superoxide dismutases whose cellular function is to reduce 
harmful ROS in cells.39  The hydrogen peroxide product can then oxidize various 
cellular components, however due to proximity, the PIP3 deactivator and tumor 
suppressor PTEN is a more likely target.35  The catalytically active cysteine residue 
C124, which normally dephosphorylates PIP3, is oxidized and forms a disulfide bond 
with C71 on the protein.40  This reversible oxidation cycle is completed when Trx 
reduces PTEN, exposing the free thiols so that C124 can dephosphorylate PIP3.35  
Dephosphorylation by catalytic cysteine residues is common among PTP family 
members including PTEN because the pKa of the active site cysteine is much lower 
than the average free thiol (pka=4-6.5).41  This allows the generation of a cysteinyl 
phosphate intermediate within the enzyme that is then hydrolyzed.41   This 
enzymatic process highlights cysteine sensitivity to protein microenvironments and 
redox chemistry upon ROS generation.   
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 Basal levels of ROS are a vital part of cell signaling.  To avoid the consequences 
of overproduction as previously described, intracellular species are used as buffers to 
reduce and eliminate ROS.  Common ROS buffer systems include Trx and Prx with 
a lesser contribution from GSH:GSSG.33  Trx has been shown to undergo significant 
oxidation upon ROS generation in response to EGF signaling and Prx can efficiently 
eliminate hydrogen peroxide at a rate constant of 105-108 M-1s-1.42-43  GSH, although 
abundant at millimolar concentrations, is too slow at reducing ROS to be considered 
effective.44  ROS derived cell signaling at these basal levels range the EGF signaling 
pathway as previously described and provide a system of checks and balances to 
maintain normal cell function.   
 
1.2 Role of Cysteine as it Relates to Reactive Oxygen Species 
1.2.1 Cysteine Oxidation and Disulfide Bond Formation 
Cysteine is one of the least abundant amino acids but is usually found in 
functionally important locations due to the free thiol side chain.  The free thiol 
pKa=8-9 and is closest to physiological pH (7.4) giving rise to high sensitivity to 
minute changes in the protein environment.45  For comparison, the next closest pKa 
to physiological pH is pKa=6.0 for histidine side chains.  Since the thiol group has a 
larger atomic radius and lower dissociation energy between the S-H bond, it can 
participate in both nucleophilic and redox chemistry.  Free thiols can be oxidized 
multiple times via ROS: reversibly to form either a disulfide bond or sulfenic acid, 
but irreversibly to form either sulfinic or sulfonic acid.   
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Figure 1.3  Oxidative PTMs of cysteine residues.  The cysteine free thiol (S-2) can 
be oxidized to form either a disulfide bond (S-1) or sulfenic acid (S0) reversibly.  The 
disulfide bond can also be reversibly oxidized to form sulfenic acid.  Sulfenic acid 
can then be irreversibly oxidized to sulfinic acid (S+2), which can further be 
irreversibly oxidized to sulfonic acid (S+4).   
 
Other post-translational modifications include nitrosylation and glutathionylation.45  
With these unique properties, cysteine residues play a variety of cellular roles: they 
can bind metal ions and make up the iron-sulfur clusters in ferredoxins, act as 
catalytic nucleophiles in caspases, adopt regulatory roles in kinases such as the 
EGFR, form structural disulfides seen in keratin, and act as redox catalytic sites for 
PTEN.46-50  Two significant examples of ROS effects on cysteine residues as it 
relates to EGF signaling are the oxidation of EGFR and AKT.  In the ATP-binding 
pocket of EGFR, C797 has been shown to undergo modification due to ROS 
generated by EGF signaling.33  Carroll et. al. has demonstrated that upon EGF 
addition, oxidation of C797 to form the sulfenylated product, increased EGFR kinase 
activity by approximately five-fold.33  This residue, interestingly, is conserved 
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within nine other receptor and non-receptor tyrosine kinases and leads to an increase 
in downstream signaling.33, 51  Another major component of the EGF signaling 
pathway, AKT, has been shown to undergo sulfenic acid modification at C124 to 
inactivate the kinase.52  To protect C124 from ROS-induced oxidation, researchers 
have shown that an overexpression of Grx sustains AKT phosphorylation.53  The 
adverse roles cysteine can perform make this residue a target for studying protein 
function and disease related to cysteine mutation and modification. 
 
1.2.2 Monitoring Cysteine Reactivity in Living Cells 
One way to effectively monitor cysteine reactivity and modification is by 
exploiting its nucleophilicity.  Iodoacetamide alkyne is highly electrophilic probe 
that has shown great utility when used to monitor cysteine reactivity within a 
proteome.54  In proteomics experiments, after treating cell lysate with IA-alkyne, 
copper(I)-catalyzed azide-alkyne cycloaddition can be used to incorporate a reporter 
group which can be a fluorescent tag such as Rhodamine azide for in-gel 
fluorescence experiments, or isotopically labeled azo tags developed for quantitative 
mass spec analysis.54   
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Figure 1.4  Use of Iodoacetamide alkyne to probe the proteome analyzed by in-
gel fluorescence and mass spectrometric methods (adapted from Weerapana et. 
al., 55).   Iodoacetamide alkyne specifically labels cysteine residues available 
throughout the proteome.  The alkyne handle is then available for click chemistry 
with either a fluorescent tag that can be used to monitor in-gel fluorescence (A) or a 
biotinylated tag that can be used to isolate tagged proteins via streptavidin bead 
enrichment (B).  The isolated proteins can then be digested with trypsin for peptide 
analysis and the tag can be cleaved for site of labeling analysis via mass 
spectrometry. 
 
However since cysteine reactivity is highly influenced by the protein 
microenvironment, more accurate data would be obtained if labeling could occur in 
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living cells and although IA-alkyne is cell-permeable, it is cytotoxic.56  Therefore a 
α-bromomethyl ketone electrophile was developed by Dr. Masahiro Abo of the 
Weerapana lab.56   
 
 
 
Figure 1.5  Caged electrophile for live cell labeling and analysis via mass 
spectrometry (adapted from Abo et. al., 56).  On the top the structure of the caged 
probe and uncaged electrophile are shown.  The bottom images show that once 
irradiated with UV light, cells can be harvested, lysed, and prepared for analysis via 
mass spec. 
His probe is a caged electrophile that can accumulate in cells without cytotoxic 
effects up to 500µM.56  To label proteins once cells have been treated with the 
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caged-BK probe, they are irradiated with UV light to uncage the probe and expose 
the BK electrophile.56  Cells can then be harvested, lysed, and subjected to CuACC 
for in-gel fluorescence or mass spec analysis.56  Once the caged-BK labeling 
protocol was optimized, A431 cells were used to observe cysteine reactivity upon 
EGF stimulation due to their overexpression of EGFR.56  This experiment gave 
information about the oxidative modifications on cysteine from physiological 
production of ROS.  The major findings were that upon EGF stimulation, a large 
number of cysteines decreased reactivity when compared to the control sample 
without EGF stimulation.56   
 
 
 
Figure 1.6  Results comparing cysteine oxidation in cells with and without EGF 
stimulation (adapted from Abo et. al., 56).  Left: sample preparation work-flow 
leading to LC-MS/MS analysis.  Right: the number of cysteine residues labeled for 
the control and EGF samples in a particular RH/L range.  The heavy to light ratio 
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(RH/L) shows that upon EGF stimulation, cysteine oxidation causes a loss of labeling 
in the overall proteome therefore increasing the ratio for treated cells.   
 
This result should be anticipated since EGF stimulation is known to increase ROS 
production and therefore more cysteine residues should be oxidized.  Many of the 
cysteines modified were known to form redox-active disulfide bonds or become S-
sulfenylated thus confirming the utility of this probe.56  One of the proteins showing 
the largest shift was FABP5 with emphasis on the C120 residue.56  Since most 
studies involving FABP5 have focused on other binding site residues with minimal 
attention given to the potential disulfide bond between C120 and C127, we decided 
to investigate their role in EGF signaling further. 
 
1.3 Fatty Acid Binding Protein 5 
1.3.1 Fatty Acid Binding Protein Family 
The FABP family, or iLBP family, consists of ten members: liver (L-, 1), heart 
(H-, 3), adipocyte (A-, 4), epidermal (E-, 5), ileal (I-, 2), brain (B-, 7), myelin (M-, 
8), gastrophin and ileal (Il-, 6), testis (T-, 9) and FABP12.57-58   
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Figure 1.7  Sequence homology between FABP family members. FABP family 
members’ sequences were taken from UniProt database and aligned via Clustal 
Omega.  The notation below specific residues indicates how conserved they are.  A 
single dot shows that a specific amino acid occurs relatively frequently in that 
position, a double dot shows that the amino acid occurs in almost all family 
members at that position, and a star denotes that a specific amino acid is conserved 
among all family members.   
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Although their sequence similarity ranges from 38-70%, three structural defining 
features are conserved throughout the family: the β-clam structure with five anti-
parallel β-strands on each side, an α-helical lid, and a hydrophobic binding pocket 
for fatty acids and lipids.58-59  Ligands are typically bound in a 1:1 ratio with the 
exception of L-FABP, which is able to bind two fatty acids simultaneously.58  
Typical substrates include but are not limited to palmitic, stearic, oleic, arachidonic, 
and linoleic acids, lysophospholipids, eicosanoids, and retinoids.57  The sequence 
variety distinguishes each FABP’s function and ligand specificity.  Unique to 
FABP5 are its cysteine residues.  There are six total throughout the protein including 
C43, C47, C67, and C87 which are completely unique and C120 and C127 which are 
both also found in M-FABP, but only one of the two cysteines in the binding pocket 
are found in other FABP family members.60  The only FABP with a proposed 
disulfide bond is FABP5 between C120 and C127.  Technically C67 and C87 are 
close together in the crystal structure of FABP5 however after crystal structure 
refinement, the electron density map indicated that a disulfide bridge was not present 
and when one was superimposed, the model protein did not match the electron 
density map.60-61  Although M-FABP has two cysteine residues in the binding pocket 
and despite biochemical evidence, a disulfide bond isn’t thought to exist based on 
the S-S distance from X-ray structure analysis.62  The other binding pocket residues 
in FABP5, R109, R129, and Y131 are relatively well conserved throughout the iLBP 
family with R129 found in all members and R109 and Y131 found in most 
members.57  Other residues of functional interest, including the nuclear localization 
signal residues, are well conserved however the activating switches of FABP5 (M35 
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and L60) are unique to that protein.57  Deviations in the activating switch regions 
account for the different ligand binding profiles for each member of the iLBP family. 
FABPs constitute 1-5% of all cytosolic proteins and the expression of a 
particular FABP is not limited to one specific cell type.63  The protein expression 
levels are indicative of the relative amount of fatty acid present and lipid metabolism 
each cell type is involved in. 57 Therefore with such divergence between expression 
and ligand binding, it should come as no surprise that a multitude of cellular 
functions has been proposed for this family of proteins.  Most proposals center on 
the theory that the roles of FABPs are to 1) solubilize hydrophobic molecules, 2) 
shuttle ligands to their appropriate location in the cell, and 3) protect their substrates 
from peroxidation.57, 64  One of the best-studied roles of FABPs is their nuclear 
transport of fatty acids to the PPAR nuclear transcription factors, which regulate 
transcription of multiple FABPs leading towards cell survival and proliferation in 
cancer as described previously.  Other diseases implicated in FABP associated 
pathways include psoriasis, diabetes, obesity, and atherosclerosis.58  The incredibly 
varied ligand binding profile of FABPs has made the development of drugs difficult.  
Many current small molecule drugs under investigation are modeled after or 
compared to small-molecule inhibitor BMS309403, derived from different 
carbazole- and indole- inhibitors, which bind A-FABP with high affinity and 
selectivity over other FABPs to treat atherosclerotic lesions.65-67  Given the 
difficulties of designing effective drugs with high affinity for specific FABPs, 
knowledge regarding the contributions of all residues within the FABP binding 
pocket is essential for the development of inhibitors to treat disease. 
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1.3.2 Cellular Function and Cancer Relevance 
FABP5 was originally discovered in keratinocytes of psoriasis patients; a 
disease characterized by rapid cell turnover and disordered lipid metabolism.68   It is 
mainly expressed in epidermal cells of the skin but is also expressed in tongue, 
adipose tissue, dendritic cell, mammary gland, brain, kidney, liver, lung, and testis 
tissues.69-71  Ligands commonly bound include a wide variety of saturated and 
unsaturated fatty acids including stearic, linoleic, palmitic, oleic, arachidonic, 
eicosapentanenoic, and docosahexaenoic acid, however only those that can adopt a 
U-shape versus L-shape conformation activate the protein for nuclear 
translocation.72-73  FABP5 can also bind other lipophilic compounds including 
retinoic acid, which has been linked to cancer via the activation of the PPAR 
pathway.   
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Figure 1.8  Relevance of FABP5 in retinoic acid signaling pathway (adapted 
from van de Pavert et. al., 74).  Retinol from the blood stream is transported into 
cell cytoplasm via STRA6 where it is converted into retinoic acid.  Retinoic acid can 
then be taken to the nucleus by either CRABP2, which delivers it to signal nuclear 
receptors RAR and RXR causing growth inhibition, or FABP5, which signals 
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nuclear receptors PPARβ and RXR to stimulate a positive feedback loop for cell 
growth. 
 
Retinol, or vitamin A, is obtained from dietary intake and stored in the liver.74  
There, it complexes with RBP4 which can be taken up by cells via STRA6.74  Once 
in the cytoplasm, retinol is converted to retinal via retinol dehydrogenase then to 
retinoic acid by RALDH2.74  Following the retinoic acid pathway, either FABP5 or 
CRABP-II binds the substrate and transports it to the nucleus.74  FABP5 specifically 
interacts with nuclear receptor PPARβ which controls keratinocyte differentiation, 
counteracts the apoptotic role of TNF-α, and upregulates the expression of FABP, 
VEGF, and PDK1, creating a positive feedback loop.75-76  CRABP-II specifically 
interacts with RAR, which promotes growth inhibition.77  Note that both PPARβ and 
RAR must form a heterodimer with RXR to be able to bind promoter regions and 
activate transcription.76  In normally functioning cells, CRABP-II and FABP5 are 
expressed such that the relative ratio of CRABP-II:FABP5 is above one.77  
Combined with a stronger binding affinity for the CRABP-II-RA-RAR complex than 
the FABP5-RA-PPARβ complex and free fatty acids outcompeting RA, rampant cell 
proliferation is kept in check.77-78  In cases of higher-grade tumors taken from ER-
negative breast cancer patients, FABP5 is upregulated, causing resistance to retinoic 
acid therapy and poorer prognosis.77  FABP5 is upregulated when EGF activates NF-
κB through the PI3K/AKT pathway as described previously.77  Since the major 
function of fatty acid binding proteins relates to metabolism there are carcinogenic 
implications with the misregulation of all members of the FABP family.79  
	 23	
1.3.3 Binding Pocket and the Relevance of Cysteine Residues 
FABP5 (also known as E-FABP, PA-FABP, C-FABP, K-FABP, or mal1) is a 
15kDa cytosolic protein that transports long chain fatty acids to the nucleus for 
cellular signaling.72, 80    
 
 
Figure 1.9  Crystal structure of FABP5 bound to linoleic acid (PDB: 4LKT).  
The left image shows the entire structure of FABP5 with binding site residues R109 
and R129 in light blue and Y131 in dark blue, C120 and C127 in red, and the 
remaining cysteine residues in yellow.  The right image shows FABP5 from the 
perspective of looking into the binding pocket from the entryway made by the α-
helical lid where R109 and R129 in light blue, Y131 in dark blue, all cysteine 
residues in yellow, and bound linoleic acid in red.  The two cysteine residues 
overlapped in this image by the bound fatty acid are C120 and C127 from left to 
right respectively. 
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The protein has a highly conserved β-clam structure with two orthogonal β-
sheets with five anti-parallel β-strands each.  There is also an α-helical lid with a 
helix-turn-helix motif, which encloses the bound fatty acid during nuclear 
transport.61  Although FABP5 can bind a variety of saturated and unsaturated fatty 
acids, those that are polyunsaturated and have the ability to adopt more of a U-shape 
conformation disrupt the β2 portal loop.72  Disruption of the portal loop causes the α-
helical lid to enclose the fatty acid and expose the nuclear localization signal region 
of the protein made up of residues K24, K34, and R33.72  Long chain fatty acids that 
bind FABP5 but have a more L-shape configuration are not fully enclosed within the 
binding pocket with the fatty acid tail exposed to solvent at the portal loop region.72  
This prevents interaction between the M35 residue of the α2 helix and L60 residue of 
the β2 loop, which act as the “activating switches” for nuclear transport.72  The 
interior of the protein is lined with hydrophobic side chains that stabilize the fatty 
acid alkyl tail via van der Waals forces and a binding site composed of R109, R129, 
and Y131 which interact with the carboxylic head group.  The strongest interaction is 
the salt bridge formed with R129 with hydrogen bonding to the other binding site 
residues.72  Interestingly two cysteine residues are located close to the binding site 
with C120 near the gamma carbon of the fatty acid alkyl chain.  Previous 
crystallographic studies have determined that these two cysteine residues are close 
enough for disulfide bond formation.  The most recent findings from X-ray 
crystallography indicate that when a fatty acid is bound, the potential disulfide bond 
is reduced and in apoprotein there is a mixture of disulfide bound and sulfhydryl 
forms of the cysteine residues.72  Mass spectrometry studies have also provided 
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evidence that these residues may form a disulfide bond through S-sulphenylation 
studies.  Yang et. al. showed that upon treatment with H2O2, C127 was more 
sulphenated than C120 suggesting that S-sulphenylation of C127 was responsible for 
disulfide bond formation.81  Otherwise, few studies have focused on the biological 
relevance of these cysteine residues and their effects on FABP5’s activity.   
 
1.4  Experimental Goals 
Given the functional relevance of cysteine residues and their location in the 
binding pocket of FABP5, our aims for this project are to characterize the role of 
C120 and probe the role of disulfide bond formation in FABP5 within the context of 
EGF signaling.  In order to characterize the C120 residue, WT FABP5 along with 
the following mutants: C120S, C127S, C120/127S, and R109A will be 
recombinantly expressed in E. coli.  Fluorescence assays will then be optimized to 
monitor cysteine reactivity under various conditions including oxidation and 
reduction via GSH/GSSG and in the presence of palmitic acid.  We then propose to 
transfect A431 human cells to either over express or knock out FABP5.  This will 
allow us to observe phenotypic characteristics and allow for studies using western 
blot and phosphoproteomic techniques to understand the role of FABP5 upon EGF 
stimulation. 
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Chapter 2:  Experiments and Results 
2.1  Recombinant Expression of WT and Mutant FABP5 
 WT FABP5 was first cloned into a pET-DUET vector in BL21 cells.  Next, the 
mutants C120S, C127S, and C120/127S were made and also expressed in BL21 cells.  
All proteins were then overexpressed with IPTG induction and purified using nickel 
columns (to remove all other proteins), PD10 columns (to remove the excess imidazole 
salt), and then hydroxyalkoxypropyl dextran columns (to remove any bound fatty acids to 
FABP5) as shown in Figure 2.1.  
A      B 
    
Figure 2.1  Coomassie images of the purification of WT and all mutant FABP5 
overexpression large-scale growths.  The order of gel A (from left to right) is: Protein 
ladder (R), WT protein lysate, WT protein after 25mM imidazole wash on a Ni column, 
WT protein final purified sample after using a PD10 column and hydroxyalkoxypropyl 
dextran column, empty lane, C120S protein lysate, C120S protein after 25mM imidazole 
wash on a Ni column, and C120S protein final purified sample after using a PD10 
column and hydroxyalkoxypropyl dextran column followed by empty lanes (saved as 
05052016gel1).   The order of gel B (from left to right) reflects the same steps in the 
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purification process as gel A, however after the lane with protein ladder (R), the order of 
protein is C127S then C120/127S (saved as 05052016gel2).   
 
Once all proteins were confirmed to overexpress and purify successfully, Figure 2.2 was 
used to show that clean purification was possible for each FABP5 variant and that a 
Bradford assay was sufficient to determine protein concentration.   
 
Figure 2.2  Coomassie image of purified WT and all mutant FABP5.  The order of the 
gel (from left to right) is blank lanes, protein fluorescent ladder (F) (which should not 
appear with any bands), WT FABP5, C120S FABP5, C127S FABP5, C120/127S 
FABP5, protein ladder (R), and more blank lanes (saved as 02112016). 
 
The next step was to determine the appropriate fluorophore to use in the fluorescence 
assays.  
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2.2  Development of Fluorescence Assays 
The purpose of these assays was to test the hypothesis that the disulfide bond that 
may exist between C120 and C127 may play a role in fatty acid binding.  To begin, two 
fluorophores were purchased, DAUDA and 1,8-ANS, because of their frequent use in 
previous publications.  DAUDA is implemented less frequently, however it’s fatty acid 
tail (Figure 2.3 A) makes it an interesting candidate for the assays.  1,8-ANS is the most 
commonly used fluorophore to study FABP5, giving a fluorescent signal upon interaction 
with a hydrophobic environment such as the binding pocket of FABP5.82   
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A              B 
   
 
C 
 
D 
 
	 30	
Figure 2.3  Evaluating fluorophores for FABP5 fluorescence assays.  The fluorophore 
structures shown in A and B are DAUDA and 1,8-ANS respectively.  The graph, C, 
depicts the fluorescence of DAUDA with and without protein present (saved as DAUDA 
development of fluorescence assay).  The graph, D, depicts the fluorescence of 1,8-ANS 
with and without protein present (saved as 1,8-ANS development of fluorescence assays). 
 
 After many replicates, the fluorophores 1,8-ANS was chosen for the remaining 
fluorescence assays.  Although DAUDA’s fatty acid tail made it a promising candidate to 
specifically target and fluoresce with FABP5, 1,8-ANS showed a stronger fluorescence 
signal at the same concentrations and less variability from assay to assay.  There is also 
more published information and established protocols available on the binding of 1,8-
ANS to FABP5.  The first assay to be performed determined the dissociation constant of 
1,8-ANS to WT, C120S, C127S, and C120/127S FABP5 (Figure 2.4).  All assays were 
repeated with three technical and three biological replicates and all analysis was 
completed using GraphPad Prism 5.0 software. 
 
 
 
 
 
 
 
 
	 31	
A 
 
B 
 
Figure 2.4  Assay type 1 with WT and all mutant FABP5.  Graph A shows the binding 
curve of 1,8-ANS to each protein variant as protein concentration increases (saved as 
Assay Type 1 final graph).  Graph B compares the dissociation constant of 1,8-ANS to 
each protein variant (saved as KD Assay Type 1 final graph). 
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 The dissociation constant of 1,8-ANS with WT, C120S, C127S, and C120/127S is 
21.21uM ±3.148, 6.930uM ±0.8661, 15.59uM ±5.349, and 8.709uM ±3.024 respectively.  
T-test results indicate that all values are significant except when comparing WT versus 
C127S protein.  Published dissociation constants under the same conditions only exist for 
WT FABP5 and 1,8-ANS equal to 6.57uM.72  The discrepancy between the published 
value and data obtained is something to note, however in this discussion we are more 
interested in comparing the different protein mutants, specifically C120/127S, to WT 
FABP5.  From these dissociation constants, we can say that the C120S and C120/127S 
mutants bind the fluorophore the strongest and that the WT protein binds it the weakest.   
The second assay performed determined the dissociation constant of 1,8-ANS 
with WT and C120/127S under different ratios of GSH:GSSG (Figure 2.5). Glutathione 
is a common tripeptide thiol found in cells that controls oxidation of cysteine residues.83  
The concentration of GSH:GSSG was kept at a constant 5mM, the same relative 
concentration in most mammalian cells.84  In these assays, glutathione was chosen due to 
it’s physiological relevance with monitoring cysteine oxidation.  Three ratios of 
GSH:GSSG were used (1:10, 1:1, and 10:1) where a ratio of 1:10 denotes 0.5mM GSH to 
4.5mM GSSG, 1:1 denotes a ratio of 2.5mM GSH to 2.5mM GSSG, and a ratio of 10:1 is 
4.5mM GSH to 0.5mM GSSG.  Therefore a 1:10 ratio should oxidize all cysteine 
residues and a 10:1 ratio should reduce all cysteine residues to free thiols. 
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A 
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Figure 2.5  Assay type 2 with WT and C120/127S FABP5.  Graph A shows the 
binding curve of 1,8-ANS to each protein as protein concentration increases in the 
presence of different GSH:GSSG ratios (saved as Assay Type 2 final graph).  Graph B 
compares the dissociation constant of 1,8-ANS to each protein under each GSH:GSSG 
scenario (saved as KD Assay Type 2 final graph). 
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 The dissociation constant of 1,8-ANS with WT FABP5 at 1:10, 1:1, and 10:1 
GSH:GSSG is 6.386uM ±1.910, 16.15uM ±4.111, and 34.23uM ±23.85 respectively.  
The dissociation constant of 1,8-ANS with C120/127S FABP5 is 3.050uM ±0.6715, 
3.395uM ±0.6682, and 4.046uM ±0.6265 respectively.  T-test results indicate that 
between all WT samples, the only significant difference is between WT 1:1 and WT 10:1, 
between all C120/127S samples there is no significance, and between all WT versus 
C120/127S samples they are all significant.  The results of the T-test are interesting 
because it shows that the difference between WT sample 1:1 and 10:1 are significant 
however the difference between 1:10 and 10:1 are not.  However, the fact that a change in 
the dissociation constant for the WT protein upon various levels of GSH:GSSG while the 
C120/127S samples remain constant suggests a potential role for these cysteine residues 
in protein function.  
Finally, the third assay performed determined the binding constant of fatty acid 
palmitic acid to WT FABP5 and all mutants by out-competing 1,8-ANS (Figure 2.6).   
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Figure 2.6  Assay type 3 with WT and all mutant FABP5.  Picture A shows the 
structure of palmitic acid used.  Graph B shows the competition of 1,8-ANS with palmitic 
acid as fatty acid concentration is increased for each protein variant (saved as Assay Type 
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3 final).  Graph C compares the binding constant of palmitic acid to each protein variant 
(saved as KI Assay Type 3 final). 
 
 The binding constant of 1,8-ANS with WT, C120S, C127S, and C120/127S 
FABP5 is 0.2020uM ±0.07479, 0.09048uM ±0.03489, 0.08767uM ±0.05300, and 
0.01822uM ±0.05098 respectively.  T-test results indicate that all comparisons are 
significant except for C120S versus C120/127S samples.  This assay shows that the 
mutations made to each cysteine residue affect fatty acid binding to the protein; more 
specifically that single mutations C120S and C127S have approximately the same effect 
on reducing binding affinity and that C120/127S has the greatest effect on fatty acid 
binding.  This data suggests that each cysteine residue plays a role in fatty acid binding 
instead of one specific residue.  Therefore a disulfide bond may indeed play a role in 
stronger fatty acid binding since any implications due to a change in local electronics is 
nullified as each mutation is to a serine residue.  Taking into account the results from 
Figure 2.5 with Figure 2.6, perhaps the disulfide bond is present and plays a role with 
both the fluorophore and palmitic acid however the interactions between each of them are 
different.  To test this theory, future experiments should repeat the third assay type under 
the various GSH:GSSG ratios of assay type 2 to directly observe fatty acid binding in 
different reductive/oxidative environments.  At this point it is important to note that we 
still cannot definitively state whether a disulfide bond is present and not the effects of a 
single cysteine residue, but the results thus far have not refuted our hypothesis.  Next, we 
sought to determine the effects of FABP5 expression in cells.   
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2.3  Expression of FABP5 in Mammalian Cells 
 The first step in determining the effects of FABP5 expression in mammalian cells 
is to determine the best cell line to use.  Previous work has focused on the use of A431 
cells since EGFR is highly overexpressed compared to other cell lines.56  However, 
transfection efficiency with Lipofectamine 2000 is much lower than other cell lines 
according to ThermoFisher Scientific.  Therefore we looked at inherent FABP5 
expression within three cell lines as shown in Figure 2.7 to help make the best choice for 
transfections.   
 
Figure 2.7  Western Blot of FABP5 in various mammalian cell lines.  The above 
figure displays the intrinsic amount of FABP5 produced in three cell lines (from left to 
right):  A431, A431, HEK293T, and SK-OV-3 cells (saved as 11292016).   
 
Therefore since transfection efficiency is the lowest with A431 cells, and the endogenous 
amount of FABP5 in HEK293T and SK-OV-3 is relatively similar, either cell line would 
be a viable alternative to use for transfections.   
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Chapter 3: Conclusions and Future Directions 
3.1  Summary of Results and Conclusions 
 The hypothesis of these experiments was that a disulfide bond might be present 
between residues C120 and C127 in FABP5 that plays a role in protein function.  After 
completing a multitude of fluorescence assays it is apparent that the WT versus 
C120/127S FABP5 protein show different trends.  Although it appears to support our 
theory, this data does not completely confirm the presence of a disulfide bond nor can we 
draw any direct conclusions about how the potential disulfide bond affects protein 
function.  More experiments need to be completed to obtain the full picture of how these 
residues play a role in FABP5.  Future studies should also include experiments within 
live cells to determine the effects overexpression and knocking out FABP5 has on 
cellular function as it relates to the EGF signaling pathway.   
 
3.2  Future Directions 
3.2.1  Transfections into Mammalian Cells 
 The next step in exploring the role of FABP5 as it relates to EGF signaling is to 
transfect mammalian cells to either overexpress the protein (via transient transfections) or 
knock-down protein expression (via viral transfections).  Transient transfections will 
increase protein expression but the effects will not last.  In transient transfections, 
pcDNA is taken up by cells with the help of a mixture of polycationic and neutral lipids 
sold as Lipofectamine.  The purified pcDNA and Lipofectamine complexes so that the 
positively charged head group of the lipids interacts with the negatively charged 
pcDNA.85  Once added to cells, the positively charged lipids bring the pcDNA to the 
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negatively charged cell surface where it can interact with the mammalian cells.85  The 
complex then enters the cell via endocytosis and once in the cell, the pcDNA begins 
transcription of FABP5.85  Other methods to overexpress protein in mammalian cells 
such as the use of polybrene or electrophoresis are not as efficient at delivering pcDNA 
into cells and have poor reproducibility in comparison.85  Another transfection method 
using a lentivirus system creates a stable transfection that lasts, however this is not ideal 
for protein overexpression.  Firstly in viral transfections, pcDNA is integrated into host 
DNA which is much more difficult to achieve than just translocating foreign pcDNA to 
the nucleus so there would not be enough pcDNA copies inserted into the host DNA to 
overexpress the protein.  With transient transfections, more copies of pcDNA are 
translocated to the nucleus thus giving higher amounts of protein expression.  Also, the 
viral packaging vector has a size limit and depending on how large the pcDNA vector is, 
it might not be a viable option.   
 Viral transfections employ a lentiviral system to infect host mammalian cells with 
DNA that encodes shRNA that is used to knock down the expression of FABP5.  In this 
procedure, a second-generation system is used with three plasmids that separate the 
necessary components of a functional virus.86  Using these plasmids should not produce a 
continuously replicating virus unless the viral plasmids recombine and the resulting 
construct is packaged in a virus, which is highly unlikely energetically.86  The three 
plasmids are the transfer vector containing the gene of interest, VSV-G, and psPAX.  
VSV-G contains the necessary information to produce the envelope protein responsible 
for determining the specificity of the virus for different cell types via surface 
glycoproteins and transmembrane proteins.86   psPAX contains the necessary information 
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to produce proteins Gag, Pol, Rev, and Tat which produce the matrix, capsid, and 
nucleocapsid for Gag, reverse transcriptase and integrase for Pol, helps with nuclear 
export for Rev, and activates transcription from the LTR promotor for Tat.86  Together 
these plasmids form a viral particle that can insert shRNA for knocking down FABP5 in 
host cells.  The knock down process occurs as shRNA is produced and complexes with 
the enzyme DICER which removes the hairpin region giving siRNA.87  The siRNA is 
then complexed with RISC, which removes the complementary strand of RNA and 
targets intracellular mRNA with the complementary strand and degrading it thus 
knocking out protein expression at the mRNA level.87  Other methods of stably knocking 
down FABP5 expression include the use of other retroviral vectors (which can only infect 
dividing cells unlike lentivirus which can infect dividing and non-dividing cells) and 
adeno-associated virus (which requires the use of a helper virus and thus a more complex 
procedure).88  With the overexpression and knock-down of FABP5 protein in mammalian 
cells, it will be possible to study the role of this protein in EGF activation.  An effective 
way to monitor this would be to observe trends in protein phosphorylation, which is 
directly affected by EGF stimulation. 
 
3.2.2  Phosphoproteomics 
 Once human cells have been transfected to either overproduce or knock out 
FABP5, we can globally analyze the proteome to monitor phosphorylation using mass 
spectrometry.  To do so, phosphorylated proteins have to be tagged, enriched, and 
prepared for analysis via mass spec.  One common method to tag proteins that our lab 
already has access to is SILAC labeling.  This method employs the use of heavy isotopes 
	 41	
incorporated into amino acids used to generate proteins, specifically 13C and 15N into 
lysine and arginine residues.89  So for example, a “heavy” arginine with 13C only would 
have a 6Da difference from a “light” arginine residue with all 12C.  These “heavy” 
residues are added to culture media fed to cells until all the amino acid residues in 
proteins have been incorporated as “heavy” residues.  A general workflow of how SILAC 
labeling can be applied to phosphoproteomics is shown in Figure 3.1.   
 
3.1  Workflow for phosphoproteomics studies.  The above workflow would be a 
sufficient method of studying protein phosphorylation on a global scale. 
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In Figure 3.1, two plates of cells labeled with “heavy” and “light” residues can be used to 
distinguish phosphorylation events indicated by a yellow circle with and without EGF 
stimulation.  The lysates can then be combined without loss of information and analyzed 
via mass spec.  One of the major challenges though is the enrichment of phosphorylated 
proteins.  Although about a third of the proteome can be phosphorylated at any given 
time, the level of phosphorylation per protein is varied and specific sites may be 
phosphorylated anywhere from 1-90%.90  Phosphorylated residues include serine, 
threonine, and tyrosine but using more traditional enrichment methods in 
phosphoproteomics, tyrosine residues exhibit much fewer hits (less than 1%) via mass 
spec than physiologically relevant.91   Traditional methods of phosphorylated protein 
enrichment center around IMAC and titanium dioxide enrichment.  IMAC enrichment is 
based on the idea that phosphates will be attracted to trivalent metal ions with high 
affinity.  The metal ions are immobilized on a porous column and phosphoproteins are 
captured and eluted by changing the pH of elution buffer.90  The problem with this 
method is that proteins with many acidic residues, glutamic acid and aspartic acid, also 
bind to the immobilized metals and co-elute with phosphorylated proteins.90  Titanium 
dioxide enrichment is accomplished by binding phosphoproteins in acidic solution like an 
anion-affinity exchange column.90  The phosphorylated proteins are then eluted using a 
gradient of alkaline borate buffer containing sodium chloride.90  To prevent proteins with 
many acidic residues without any phosphorylation from binding to the column, 2,5-
dihydroxy benzoic acid is added to the protein before being subjected to the column.90  In 
this way, carboxylic acid groups are out-competed while phosphoproteins still bind the 
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column.90  However, neither of these methods address the issue of low tyrosine 
phosphoprotein counts.  Phosphorylated tyrosine residues have a much shorter half-life 
than serine and threonine residues unless protected by SH2 and PTP domains.91  Previous 
methods to enrich phosphorylated tyrosine proteins have focused on antibodies, however 
due to cost, this was not feasible for large-scale production.92  Very recently, a new 
approach modifying the SH2 domain of Src protein to tightly bind phosphorylated 
tyrosine residues has been successfully used to increase the amount of phosphotyrosine 
peptides identified via mass spec.92  By making mutations T183V, C188A, and K206L, 
the SH2 domain binds phosphorylated tyrosine residues with much greater affinity, 
yielding thousands more hits via mass spec analysis.92  This “superbinder” can be mass-
produced in E.coli and bound to a Ni column to create the final affinity column for 
phosphotyrosine peptides.92  Once the phosphoproteins are collected, the superbinder 
complexes can be eluted with imidazole, desalted, and separated via acetonitrile with 
TFA on an IMAC column.92  This affinity purification strategy yields accurate and high-
throughput data regarding tyrosine phosphorylation in the proteome. 
 With these enrichment strategies in mind, mass spec analysis for these 
phosphoproteomics studies will focus on identifying the global changes in protein 
phosphorylation upon EGF stimulation.  Since FABP5 has been shown to oxidize readily 
due to ROS generated by EGF stimulation, varying the expression levels of FABP5 and 
the cysteine mutants should yield interesting data regarding proteome phosphorylation 
since the PPARβ/δ targeted by FABP5 targets the PDK1 gene that phosphorylates ATK 
and the FABP5 gene.75-76  Such changes within the proteome require high sensitivity and 
resolution, which cannot be provided by simple LC-MS systems.  The use of an LTQ 
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Orbitrap mass spectrometer is necessary for such delicate studies due to its greatly 
improved mass accuracy and high resolution over simpler LC-MS models.93  This 
improvement is a direct result from trapping ions in an electrostatic field via the Orbitrap 
instead of RF voltage.93  In an LTQ Orbitrap, after ions have been generated, they travel 
to a linear ion trap where they are stored and ejected as packages thus allowing a 
continuous source of ions to be used.93  Next they are sent to the C-trap, which is shaped 
to eliminate any interfering particles and improve the signal-to-noise ratio.93  The C-trap 
then pulses ions to the Orbitrap with a trajectory that induces an elliptical spin pathway 
characteristic to each m/z thus giving excellent m/z separation and resolution.93  With 
such a powerful instrument, LC/LC-MS/MS experiments can be used for these 
phosphoproteomics studies; however for more specific data regarding singular 
phosphorylation events on specific components of the EGF pathway, the use of 
antibodies would be appropriate.   
 
3.2.3  Western Blotting 
 Another technique that can be used to monitor the role of FABP5 in cells is to 
observe the phosphorylation of specific components in the EGF signaling pathway.  By 
using western blotting to target specific proteins that are phosphorylated, we can observe 
changes in phosphorylation at different points in the pathway.  Again, ideally A431 cells 
would be used due to their higher expression levels of EGFR that can be stimulated upon 
treatment with EGF.  The basic premise of western blot imaging via an indirect ELISA 
technique is shown in Figure 3.2. 
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3.2  Western Blot technique to monitor protein phosphorylation.  Western blotting 
using antibodies that specifically target phosphorylated proteins can monitor differences 
in protein phosphorylation for specific proteins in the EGF signaling pathway.  The 
protein shown in this figure is FABP5. 
 
 In Figure 3.2, the protein from a cell lysate is immobilized on a nitrocellulose 
membrane, the protein of interest is targeted with a primary antibody, and a secondary 
antibody is used to target the primary antibody and provide a measurable signal.  
Antibodies are inherently highly specific for their antigen so it is possible to have both an 
antibody for a phosphorylated protein and one without phosphorylation.  In this way, 
qualitative results can be obtained by comparing the amount of phosphorylated to non-
phosphorylated protein abundance.  To obtain quantitative results, a protein standard 
must be used in tandem with this experiment.  A list of available antibodies available for 
different components of the EGF signaling pathway is shown in Table 3.1.   
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Protein of Interest Site of phosphorylation 
targeted by antibody on 
protein 
Antibody available  
EGFR None Anti-EGFR antibody 
[EP38Y] (ab52894) 
EGFR Y1092 Anti-EGFR (phospho 
Y1092) antibody [EP774Y] 
(ab40815) 
EGFR Y1173 Anti-EGFR (phospho 
Y1173) antibody [E124] 
(ab32578) 
EGFR Y1086 Anti-EGFR (phospho 
Y1086) antibody [Y39] 
(ab32086) 
EGFR Y1068 Anti-EGFR (phospho 
Y1068) antibody [Y38] 
(ab32430) 
EGFR Y845 Anti-EGFR (phospho 
Y845) antibody (ab5636) 
EGFR T693 Anti-EGFR (phospho T693) 
antibody [EP2256Y] 
(ab75980) 
EGFR T654 Anti-EGFR (phospho T654) 
antibody [3F2] (ab78283) 
EGFR S1070 and S1071 Anti-EGFR (phospho 
S1070 + S1071) antibody 
[EP2259Y] (ab76300) 
EGFR S1047 Anti-EGFR (phospho 
S1047) antibody [1H9] 
(ab24918) 
PI3K (p85alpha subunit) None Anti-PI 3 Kinase p85 alpha 
antibody [EPR18702] 
(ab191606) 
PI3K (p85 subunit) Y607 Anti-PI3K p85 (phospho 
Y607) antibody (ab182651) 
PI3K (p110delta/p85alpha) None Recombinant human PI3K 
(p110 delta/p85 alpha) 
protein (ab125633) 
PI3K (p110delta) None Anti-PI 3 Kinase p110 delta 
antibody (ab1678) 
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PI3K (p85beta) Y464 Anti-PI 3 Kinase p85 beta 
(phospho Y464) antibody 
(ab138364) 
AKT None Anti-pan-AKT antibody 
(ab8805) 
AKT T308 Anti-pan-AKT (phospho 
T308) antibody (ab38449) 
AKT S473 Anti-AKT1 (phospho S473) 
antibody (ab66138) 
PTEN None Anti-PTEN antibody 
(ab31392) 
PTEN T366 Anti-PTEN (phospho T366) 
antibody [EP229] 
(ab109454) 
PTEN S370 Anti-PTEN (phospho S370) 
antibody (ab30654) 
PTEN S380, T382, T383 Anti-PTEN (phospho S380 
+ T382 + T383) antibody 
(ab131107) 
PDK1 None but can also detect 
PDK1 when Y 373 and 
Y376 are phosphorylated 
Anti-PDPK1 antibody 
[EP569Y] (ab52893) 
PDK1 S241 Anti-PDPK1 (phospho 
S241) antibody (ab32800) 
PDK1 S410 Anti-PDPK1 (phospho 
S410) antibody [EPR6157] 
(ab133461) 
PDK1 Y9 Anti-PDPK1 (phospho Y9) 
antibody (ab111863) 
 
Table 3.1  List of available antibodies for both phosphorylated and non-
phosphorylated components of the EGF signaling pathway.  Note this is not a 
complete list of all antibodies available for the different phosphorylation sites on each 
protein.  All antibodies are produced via Abcam.  When performing these experiments, it 
may be best to choose some, but not all, antibodies to start with in order to gauge how 
extensively FABP5 affects EGF signaling. 
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 With these assays it would be possible to monitor the amount of phosphorylation 
of each component in the EGF signaling pathway in cells that have been both virally 
transfected to knock out the production of FABP5 and cells that have been transiently 
transfected with FABP5 to overexpress WT, or any FABP5 mutant.  It would also be 
imperative to monitor phosphorylation levels with various amounts of EGF added to cells 
as well as the length of time cells are subjected to EGF.  One major drawback with this 
proposed series of experiments is the limitation to cell lysates.  Protein phosphorylation is 
very dynamic and more accurate data would be obtained if these experiments were done 
in living cells.   
 Procedures for ELISA based assays in living cells have been developed, however 
due to the amount of disruption at the cell surface and modification to antigens, they may 
not be a viable option for our studies.  For live cell experiments, the cells would have to 
be fixed and permeabilized to allow the antibodies access inside the cells.  Methods for 
fixation and/or permeabilization of the antigen include organic solvents and cross-
linkers.94  Organic solvents like methanol and acetone remove lipids and dehydrate the 
cells causing the proteins to precipitate on the cellular architecture.94  Cross-linkers such 
as paraformaldehyde links together antigens via free amino groups which disrupts cell 
structure less but alters the antigenicity to where the antibody may not be effective.94  
This method would then require a permeabilization step, typically accomplished with 
methanol.94  Another change needed for this protocol to work is how signal is obtained.  
Since we are also interested in studying ROS generation within cells as it relates to EGF 
signaling, it does not make sense to treat cells with hydrogen peroxide in order to gain 
signal via luminol interaction with HRP.  Therefore a new technique using quantum dots 
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has been used for excellent signal generation with even the lowest abundance proteins.95  
The advantages to using quantum dots as a signal are that they are much brighter at lower 
concentrations, can be specifically excited by one wavelength, are more stable against 
photobleaching, and can be conjugated to a secondary antibody.95  Problems with 
quantum dot solubility have been overcome via the use of a ZnS-cap and treatment with 
mercaptoacetic acid.95  Other issues that have been solved include bioconjugation to the 
antibodies.  One method of particular interest is the development of a copper free azide-
alkyne cycloaddition, “click” chemistry, based strategy where quantum dots that have 
been capped with an alkyne bearing moiety and the biomolecule is labeled with an 
azide.96  
Overall the use of an indirect based ELISA technique with western blotting is 
useful to determine specific phosphorylation patterns with respect to the components of 
the EGF signaling pathway.  Targeting proteins in living cells would provide more 
accuracy, however disruption of the cell membrane environment would likely discredit 
any accuracy gained for specific targets.  By using viral and transient transfections to 
alter FABP5 expression in cells, a multitude of experiments may be performed to 
determine its effects on protein phosphorylation upon EGF stimulation at both the global 
and protein-specific scale.   
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Chapter 4:  Materials and Methods 
4.1  Cloning and Mutagenesis 
 Forward Primer 
5’-3’ 
Reverse Primer 
5’-3’ 
Date Cloning was 
Successful 
Named 
WT GAATTGGATC
CAATGGCCAC
AGTTCAGC 
CTTAAGGTAC
CTTACTATTCT
ACTTTTTCATA
GATCCGAG 
17 August, 2015 Ptduet forw 
fabp5 and 
ptduet revr 
fabp5 
C120S CGTCATGAAC
AATGTCACCT
G 
CTCTCCACCAC
TAATTTCCCA 
22 October, 2015 FABP5_C120
S_fwd and 
FABP5_C120
S_rev 
C127S CACTCGGATC
TATGAAAAAG
TAGA 
CTGGTGACAT
TGTTCATGAC
A 
22 October, 2015 FABP5_C127
S_fwd and 
FABP5_C127
S_rev 
C120/1
27S 
GAAAGATGGG
AAATTAGTGG
TGGAGAGTGT
CATGAACAAT
GTCACCAGC 
GCTGGTGACA
TTGTTCATGAC
ACTCTCCACC
ACTAATTTCCC
ATCTTTC 
9 December, 2015 TY127pres12
0dmfwd and 
TY127pres12
0dmrev 
All into 
pcDNA 
GAATTGGTAC
CGCCATGGCC
ACAGTTC 
CTTAAGGATC
CTTACTATTCT
ACTTTTTCATA
GATCCGAG 
30 May, 2016 Fabp5pcdnafo
rward and 
fabp5pcdnare
verse 
 
Table 4.1  Primers successfully used for WT and all FABP5 mutants.  The name for 
each primer is what was used when placing the order. 
Protocol for Cloning WT FABP5 Into pET-DUET Vector: 
1.  To dilute primers : 
500× 6000𝑝𝑟𝑖𝑚𝑒𝑟 𝑚𝑜𝑙𝑒𝑐𝑢𝑙𝑎𝑟 𝑤𝑒𝑖𝑔ℎ𝑡= ℎ𝑜𝑤 𝑚𝑢𝑐ℎ 𝑤𝑎𝑡𝑒𝑟 𝑡𝑜 𝑎𝑑𝑑 𝑢𝐿 𝑓𝑜𝑟 𝑓𝑖𝑛𝑎𝑙 𝑝𝑟𝑖𝑚𝑒𝑟 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 𝑜𝑓 1𝑚𝑔/𝑚𝐿 
2.  Next dilute primers 1:10 to get a final concentration of 0.1mg/mL 
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3.  Take 1.5uL of 0.1mg/mL primer and add to 50uL total volume PCR reaction 
4.  Add 1uL of 10ng/uL plasmid template to PCR tube 
5.  Add 1uL of 10mM dNTPs 
6.  Add 10uL of pHusion reaction buffer 
7.  Add 34.5uL sterile water 
8.  Add 0.5uL pHusion polymerase 
9.  Cycling conditions for PCR reaction 
 1.  5 minutes at 98 °C 
 2.  10 seconds at 98 °C 
 3.  20 seconds at 61 °C 
 4.  45 seconds at 70 °C 
 5.  repeat steps 2-4 thirty five times 
 6.  5 minutes at 70 °C  
 7.  Leave reaction at 4 °C 
10.  Perform PCR purification 
 1.  Add 5 volumes of buffer PB to one volume of PCR reaction and mix 
 2.  Place a QIAquick column in a 2mL collection tube 
 3.  To bind DNA, apply the sample to the QIAquick column and centrifuge for 60 
seconds, and discard flow-through 
 4.  To wash, add 750uL of buffer PE, centrifuge for 60 seconds, and discard flow-
through 
 5.  Centrifuge the column one more time for one minute to remove any residual 
wash buffer 
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 6.  Put column in new tube to collect DNA 
 7.  To elute DNA, add 45uL of 1:10 EB buffer in water prewarmed to 42 °C  
 8.  Let stand for five minutes, then centrifuge 1 minute and save flow-through 
11.  Run an analytical DNA gel using 5uL of PCR reaction and 5uL dye 
12.  Restriction Digest using the following table to set up each sample (keeping the 
vector and insert separate): 
Volumes Vector Insert 
Buffer 8uL 6uL 
1st Restriction Enzyme (BamH 1) 4uL 3uL 
2nd Restriction Enzyme (Kpn 1) 4uL 3uL 
DNA from PCR Enough for 2ug 43uL (all purified DNA) 
Water Calculate 5uL 
Final Volume 80uL 60uL 
 
Table 4.2  Restriction digest volumes.  Remember to keep the vector and insert separate 
until indicated. 
13.  Let digestion occur for 1 hour at 37 °C  
14.  PCR purify and elute vector in 55uL and insert in 30uL of 1:10 EB buffer in 
water 
15.  Dephosphorylation of vector only: 
 1.  Mix 55uL of vector from elution with 4uL cutsmart NEB buffer and 2uL 
Antarctic phosphatase 
 2.  Incubate for 30 minutes at 37 °C and PCR purify in the warm room not on the 
shaker 
16.  Ligation: 
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 1.  Mix 90fM of insert with 30fM vector in 20uL final reaction with 1uL ligase 
and 2uL buffer diluted to 20uL with water 
 2.  Incubate for 30 minutes at room temperature 
 3.  Controls: without insert and without insert but with ligase 
 4.  Mix entire 20uL of ligation into 50uL competent DH5α cells and transform 
17.  Transformation: 
 1.  Incubate 50uL of competent cells on ice for 25 minutes 
 2.  Heat shock for 45 seconds at 42 °C 
 3.  Recover on ice for 2 minutes 
 4.  Add 750uL of LB media 
 5.  Grow for one hour at 37 °C 
 6.  Plate 50uL of growth overnight at 37 °C on an LB plate with ampicillin 
18.  Harvest colonies from sample plates with an inoculation loop and add to 5mL of 
LB media with ampicillin and allow to grow overnight shaking at 37 °C 
19.  Miniprep 
 1.  Pellet 5mL overnight bacterial culture by centrifugation (~17,900xg for 1 
minute at room temperature) 
 2.  Resuspend pelleted bacterial cells in 250uL Buffer P1 and transfer to a 
microcentrifuge tube 
 3.  Add 250uL Buffer P2 and mix thoroughly by inverting the tube 6 times 
 4.  Add 350uL Buffer N3 and mix by inverting the tube 6 times 
 5.  Centrifuge for 10 minutes at 17,900xg at room temperature 
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 6.  Apply the supernatant to a QIAprep spin column and centrifuge for 1 minute at 
17,900xg 
 7.  Discard flow-through and add 750uL of Buffer PE and centrifuge for another 
minute at 17,900xg 
 8.  Discard flow-through and centrifuge again for another minute at 17,900xg to 
remove any remaining buffer 
 9.  Place the QIAprep column in a clean 1.5mL microcentrifuge tube and add 
35uL of 1:10 EB buffer in water prewarmed to 42 °C 
 10.  Let stand for 5 minutes at room temperature then spin at 17,900xg for  2 
minutes and save the supernatant 
20.  Take DNA concentrations and prepare samples for sequencing via Genewiz 
(80ng/uL in 10uL total volume) 
21.  If sequencing is correct, transform purified DNA into BL21 cells and make 
glycerol stocks 
 
Protocol for 5’ Add-on Mutagenesis for Single Mutations: 
1. PCR components: 
1. 1uL of 10ng/uL plasmid 
2. 1.5uL of each primer at 0.1mg/mL 
3. 1uL of 10mM dNTPs 
4. 10uL pHusion buffer 
5. 0.5uL of pHusion polymerase 
6. 34.5uL water 
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2. Cycling Conditions: 
1. 30 seconds at 98 °C 
2. 10 seconds at 98 °C 
3. 30 seconds at 58 °C for C120S mutant or 30 seconds at 57 °C for C127S 
mutant 
4. 4 minutes at 72 °C 
5. Repeat steps 2-4 thirty times 
6. 2 minutes at 72 °C 
7. Hold at 4 °C 
3. Purify PCR reaction and run DNA analytical gel 
4. Phosphorylation: 
1. Reaction Mixture 
1. 2uL PCR prep 
2. 0.5uL T4 polynucleotide kinase 
3. 2.5uL of 10x ligase buffer (not kinase buffer since it doesn’t have ATP) 
4. 20.5uL water 
2. Incubations 
1. 30 minutes at 37 °C 
2. 10 minutes at 70 °C to deactivate the kinase 
3. Hold at 4 °C 
5.  Ligation 
1.  Reaction Mixture 
1.  3.5uL phosphorylation reaction 
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2.  0.5uL T4 ligase 
3.  4uL of 5x ligation buffer 
4.  12uL water 
2.  Incubate at room temperature for 30 minutes 
6.  Transform into DH5α cells 
7.  Inoculate colonies and sequence results 
8.  Transform DNA into BL21 cells 
 
Protocol for Lightning Mutagenesis for C120/127S Mutant: 
1. PCR reaction components: 
1. 2.5uL of 10x reaction buffer 
2. xuL (50ng) of DNA template 
3. xuL (62.5ng) of primer #1 
4. xuL (62.4ng) of primer #2 
5. 0.5uL of dNTP mix 
6. 0.75uL of QuikSolution reagent 
7. Add 1uL DMSO 
8. Add enough water for a final volume of 25uL 
9. Add 0.5uL QuikChange Lightning Enzyme 
2. Cycling Conditions: 
1. 2 minutes at 95 °C 
2. 20 seconds at 95 °C 
3. 1 minute at 60 °C 
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4. 6 minutes at 68 °C 
5. Repeat steps 2-4 eighteen times 
6. 5 minutes at 68 °C 
7. Hold at 4 °C 
3. Dpn1 Digest: 
1. Add 2uL of Dpn1 restriction enzyme directly to each PCR reaction 
2. Mix by pipetting up and down 
3. Incubate at 37 °C for 5 minutes 
4. Transformation: 
1. Thaw the XL10-Gold competent cells on ice 
2. Aliquot 22.5uL cells per PCR into a pre-chilled tube 
3. Add 1uL of the β-ME mix provided 
4. Swirl and incubate on ice for 2 minutes 
5. Add 1uL of Dpn1 digested PCR to cells 
6. Incubate on ice for 30 minutes 
7. Preheat NZY+ broth in a 42 °C water bath 
8. Heat pulse tubes in 42 °C for 30 seconds 
9. Incubate on ice for 2 minutes 
10. Add 0.25mL preheated NZY+ broth to each tube 
11. Incubate at 37 °C for 1 hour shaking 
12. Plate 200uL of reaction mixture on to plates 
5. Inoculate colonies, miniprep and sequence results 
6. Transform purified DNA into BL21 cells 
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Protocol for Putting FABP5 into pcDNA: 
1. Designed primers with different restriction enzyme cut sites than FABP5 in pET-
DUET vector.  For the forward primer used HindIII restriction enzyme and for the 
reverse primer used XbaI restriction enzyme.  Also included Kozak sequence on 
the forward primer (CCGCC) to promote better expression in mammalian cells 
2. Used the same PCR reagents as listed for cloning WT FABP5 into pET-DUET 
except that the plasmid was purified FABP5 (WT and all mutants) in pET-DUET.  
Primers used were also diluted the same way 
3. Cycling Conditions: 
1. 5 minutes at 98 °C 
2. 10 seconds at 98 °C 
3. 30 seconds at 60 °C 
4. 1 minute at 70 °C 
5. Repeat steps 2-4 thirty four times 
6. 5 minutes at 70 °C 
7. Hold at 4 °C 
4. The rest of the procedure is identical to the procedure for putting WT FABP5 into 
pET-DUET.  The only changes are the restriction enzymes used during the 
restriction digest and the vector used is purified pcDNA 3.1(+)A.   
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4.2  Bacterial and Mammalian Cell Culture 
Protocol for Large Scale Growths of All FABP5: 
1. Prepare 5mL overnight samples from glycerol stocks 
1. Add 5mL LB media containing 100uM ampicillin to a 15mL conical tube 
2. Dip an inoculation loop into glycerol stock and then place in sample tube 
3. Let grow overnight shaking at 37 °C 
2. Autoclave 500mL of LB media in a 2L Erlenmeyer flask for each protein sample 
and let cool overnight 
3. Add ampicillin to 2L flasks containing media until final concentration equals 
100uM 
4. Add 5mL overnight samples to each 2L flask of LB media and grow to an OD600 
of ~0.7-1.0 
5. Add IPTG to a final concentration of 1mM and let the 2L flasks swirl at 37 °C 
overnight 
6. Spin down bacterial growths using 50mL conical tubes for 15 minutes at 5000rpm 
7. Add 9mL of PBS to each cell pellet and pipette to completely resuspend before 
lysing 
8. Lyse bacteria at 95% amplitude 3x 20 buzzes each 
9. Aliquot bacteria lysates to 2mL microcentrifuge tubes and balance (should be able 
to fit one pellet into a total of four tubes) 
10. Centrifuge lysates in the cold room for 30 minutes at 1400xg 
11. Save the supernatant 
12. Purification via nickel columns: 
	 60	
1. Prepare nickel columns by adding 2mL of Ni resin to each column and 
allowing gravity to remove buffer 
2. Wash three times with water via gravity flow 
3. Wash three times with PBS via gravity flow 
4. Add saved supernatant to the column (only one type of protein per column to 
minimize any chance of contamination) and allow protein to bind the column 
via gravity flow.  Do not force protein through the column; this will take a 
substantial amount of time.  If the column appears clogged, gently resuspend 
the top layer of nickel resin until the flow returns but only if the column will 
not flow 
5. Add 3mL of 25mM imidazole to each column and elute all protein without a 
His-tag via gravity flow 
6. Add 2.5mL of 250mM imidazole to each column and collect the eluent 
7. Wash each column three times with PBS via gravity flow then store capped in 
the 4 °C fridge 
13. Purification via PD10 columns: 
1. Remove the cap and cut the tip off of each PD10 column.  Use one column 
per protein sample and do not reuse them 
2. Allow the column buffer to flow through via gravity 
3. Wash the column three times with PBS at pH 8.2 via gravity 
4. Apply saved Ni column eluent and discard flow-through 
5. Add 3mL of PBS (pH 8.2) and save the eluent 
6. Discard PD10 columns 
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14. Purification via Hydroxyalkoxypropyl Dextran columns: 
1. Add hydroxyalkoxypropyl dextran powder to the 2mL mark of each column 
2. Fill the column with acetone to pack the powder and allow it to flow through 
via gravity 
3. Wash column with PBS (pH 8.2) via gravity 
4. Apply sample from PD10 column to hydroxyalkoxypropyl dextran column 
and collect the fully purified supernatant 
15. Determine protein concentration via Bradford assay 
16.   Store all protein samples in the cold room 
 
Protocol for Mammalian Cell Culture: 
1. The three cell types previously described are all cultured differently: 
1. A431 cells require complete DMEM (addition of FBS and PSA) and the 
media has to be replaced on a specific schedule (on the third day since the last 
passage, the fifth day, the sixth day, then every day until they are confluent 
enough to be passaged).  If the cells are not monitored closely, the plate will 
suddenly die and a new stock must be thawed.  These cells also appear to have 
difficulty surviving past approximately 20-30 passages.  These cells are very 
difficult to remove from the plate with trypsin and may take over 30 minutes 
to begin to lift off of the plate 
2. SK-OV-3 cells require complete RPMI (addition of FBS and PSA) and the 
media to be replaced 1-2 times between passages.  These cells are easy to 
passage, requiring only ten minutes in trypsin to be removed from the plate.  
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They are also fully confluent in about a week’s time depending on how many 
cells were initially plated (about 20% of a 10cm diameter plate should be 
confluent in one week) 
3. HEK293T cells require complete DMEM (addition of FBS and PSA) and the 
media to be replaced maybe once before the next passage since they grow 
rapidly.  These cells are easy to passage, requiring only ten minutes in trypsin 
to be removed from the plate.  They are also fully confluent within days 
depending on how many cells were initially plated (about  20% of a 10cm 
diameter plate should be confluent in 2-3 days) 
2. To remove cells from the plate surface, trypsin is used 
1. Remove all media from the plate 
2. Add 4mL trypsin to a 10cm diameter plate of cells so that they are all covered 
3. Allow plates of cells to incubate at 37 °C for ten minutes 
4. If the cells aren’t lifting off the plate, add another 1mL of trypsin and incubate 
for another 5 minutes 
5. Once all cells are floating in trypsin, add 10mL of the appropriate media to the 
plate and collect all of the cells in 15mL conical tubes 
6. Spin cells down for 4 minutes at 200xg 
7. Remove all media and add fresh media to cell pellet 
8. Resuspend cell pellet and aliquot into new plates with fresh media 
9. Store all mammalian cells in 37 °C incubator 
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4.3  Analytical Methods 
Protocol for Assay Type 1: 
1. Dilute 1,8-ANS stock (250uM) to 50uM in ethanol 
2. Calculate protein dilutions for each concentration in 100uL total volume (0.1, 1, 
5, 10, 20, 30, 40, 50uM protein) 
3. Calculate the amount of PBS (pH 8.2) to add to protein to reach a total volume of 
99uL 
4. Add PBS (pH 8.2) first then add protein, pipetting up and down every time to 
thoroughly mix.  Also do not add samples to wells around the outside of the plate 
reader plate (only rows B-G and columns 2-11 are used) 
5. Add 1uL of 50uM 1,8-ANS for a final concentration of 500nM 1,8-ANS and only 
1% ethanol in the final sample.  Remember to pipette up and down to mix 
thoroughly and use a fresh pipette every time to avoid contamination 
6. Make blank samples with only protein in PBS (add 1uL pure ethanol instead of 
1,8-ANS to keep the amount of ethanol constant) 
7. Make each sample three times for three technical replicates per plate 
8. Repeat with two more growths for three biological replicates 
9. Settings on plate reader: 
1. Endpoint, Fluorescence, bottom read 
2. Excitation wavelength = 380nm 
3. Emission wavelength = 460nm 
4. Temperature set to 37 °C 
5. No Auto Cutoff 
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6. Sensitivity set to automatic and 5 readings 
7. Automix before the first read for 60 seconds 
8. Select the plate type as 96 Well Greiner blk/clrbtm 
9. Select reading area on the plate and hit ok 
 
Protocol for Assay Type 2: 
1. Dilute 1,8-ANS stock (250uM) to 50uM in ethanol 
2. Make stocks of GSH:GSSG 
1. 1:10 ratio as 25mM GSH with 225mM GSSG in water 
2. 1:1 ratio as 125mM GSH with 125mM GSSG in water 
3. 10:1 ratio as  225mM GSH with 25mM GSSG in water 
4. For each sample at a specific GSH:GSSG ratio, to get the appropriate 
concentration in each well add 2uL of the corresponding stock 
3. Calculate protein dilutions for each concentration in 100uL total volume (0.1, 1, 
5, 10, 20, 30, 40, and 50uM protein) only using WT and C120/127S protein 
4. Calculate the amount of PBS (pH 8.2) to ad to protein to reach a total volume of 
97uL 
5. Add PBS (pH 8.2) first then add protein to each well, pipetting up and down 
every time to thoroughly mix 
6. Add 2uL GSH:GSSG stock to each well, pipetting thoroughly and using a fresh 
pipette tip each time 
7. Duplicate these sample wells for the blank samples and make each in triplicate for 
three technical replicates 
	 65	
8. Incubate plate in the warm room at 37 °C for one hour 
9. Add 1uL of 50uM 1,8-ANS to sample wells  
10. For blank samples do not include fluorophore; instead add 1uL ethanol to keep 
ethanol concentration constant at 1% and final volume at 100uL 
11. Read using same plate reader settings as the protocol for Assay Type 1 
 
Protocol for Assay Type 3: 
1. Dilute 1,8-ANS stock (250uM) to 100uM in ethanol 
2. Dilute stocks of different palmitic acid concentrations in ethanol that will have the 
following concentrations when 0.5uL is added to 100uL total volume: 0.1, 1, 5, 
10, 15, 20, 25, and 30uM palmitic acid 
3. Calculate protein dilutions for 10uM in 100uL total volume 
4. Calculate the amount of PBS (pH 8.2) to ad to protein to reach a total volume of 
99uL 
5. Add PBS (pH 8.2) first then add protein to each well, pipetting up and down 
every time to thoroughly mix 
6. For blank samples, only add 99uL PBS 
7. Add 0.5uL palmitic acid stock to each well, pipetting thoroughly and using a fresh 
pipette tip each time 
8. Immediately add 0.5uL of 100uM 1,8-ANS to sample wells and to wells used for 
blanks with just palmitic acid 
9. Read using same plate reader settings as the protocol for Assay Type 1 
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Protocol for Western Blot: 
1. Run protein on an SDS-PAGE gel (15%) 
1. Gel Recipe for 15% (Top Layer enough for 4 gels): 
• 14.9mL water 
• 3.33mL Acrylamide 
• 6.25mL of 0.5M Tris (pH 6.8) 
• 250uL of 10% SDS in water 
• 250uL of 10% APS in water 
• 25uL TEMED 
2. Gel Recipe for 15% (Bottom Layer enough for 4 gels): 
• 9.2mL water 
• 20mL Acrylamide 
• 10mL of 1.5M Tris (pH 8.8) 
• 400uL of 10% SDS in water 
• 400uL of 10% APS in water 
• 40uL TEMED 
3. Combine all components for top and bottom layers except for APS 
4. Set up gel apparatus and fill with bottom layer (with APS added) almost to the 
top 
5. Fill the rest of the gel with ethanol and wait about 45 minutes 
6. Add APS to the top layer and pipette top layer to gel 
7. Add comb to define the wells and let sit for 45 minutes 
8. Remove comb and wrap gels in wet paper towels and store in the 4 °C fridge 
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9. To use, place gel in gel box and fill with running buffer 
10.   Determine protein concentration desired in 50uL and make samples diluted 
with PBS 
11.   Add 50uL of 2x loading dye to each sample and mix thoroughly 
12.   Create ladder sample to determine protein size when gel is finished by 
adding 20uL of 2x loading dye to “R” ladder 
13.   Aliquot all 25uL of “R” ladder into one well on the side of the gel 
14.   Aliquot 50uL of protein samples into each well of the gel 
15.   Place the lid on the gel box and run for 170 minutes at 100 volts and 400 
amps 
2. Transfer protein to membrane: 
1. Fill the tub provided with transfer buffer from the cold room 
2. Create a sandwich using the western casette 
1. Order of the sandwich:  black side of the cassette -> black sponge -> filter 
paper -> gel with protein on it -> nitrocellulose membrane  (do not touch 
with fingers) -> filter paper -> black sponge -> clear side of cassette 
2. Use a glass pipette to smooth out the gel->membrane interface so it is free 
of any bubbles 
3. Close the cassette and put the black side facing the black part of the holder 
that connects it to the voltage in the gel box and put the clear side of the 
cassette next to the red side of the holder 
4. Place an ice pack in the box 
5. Fill the gel box with transfer buffer 
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6. Run gel for 120 minutes at 70 volts 
3. When done, remove the membrane and wash for 5 minutes with TBST shaking 
4. Add ponceau stain to visualize protein lanes and to make sure the protein 
transferred 
5. Remove dye by washing membrane three times for 5 minutes each with TBST 
buffer while shaking 
6. Next add 2.5g of powdered milk in 50mL TBST to the membrane and let it shake 
for two hours at room temperature 
7. Once done, wash the membrane again three times for 5 minutes each with TBST 
buffer while shaking 
8. Allow the membrane to be exposed to the primary antibody (FABP5 rabbit 
antibody diluted 1:1000 in TBST) overnight at 4 °C in the cold room while 
shaking 
9. The next day, wash the membrane again three times for 5 minutes each with 
TBST buffer while shaking 
10.   Add secondary (anti-rabbit) antibody and allow it to shake at room temperature 
for 2 hours 
11.   Wash the membrane again three times for 5 minutes each with TBST buffer 
while shaking 
12.   Image with high sensitivity on the Bio-RAD ChemiDoc MP Imaging System 
13.   Note that all antibodies can be used multiple times (about 3-4 uses) so save them 
after each use 
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